Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The entity will undertake the installation, operation, and maintenance of sewage treatment plants
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
CRISPR-based detection enables highly specific molecular recognition
It will focus on interface between API and formulation manufacturing, reducing carbon footprint in formulation production, creating intellectual property, training next-generation scientists, and setting new industry benchmarks
Enters the high growth vitamins, minerals and supplements segment for adults, paediatrics, and animal health
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
Deepak has around 25 years of work experience with reputed companies viz. UPL Group, Teva Group, AkzoNobel India, Ranbaxy Laboratories, and Dr. Reddy’s Laboratories
This marks the fourth acquisition by Corona Remedies from multinational corporations
Subscribe To Our Newsletter & Stay Updated